<SEC-DOCUMENT>0000950170-25-002866.txt : 20250107
<SEC-HEADER>0000950170-25-002866.hdr.sgml : 20250107
<ACCEPTANCE-DATETIME>20250107163002
ACCESSION NUMBER:		0000950170-25-002866
CONFORMED SUBMISSION TYPE:	SCHEDULE 13G
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250107

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Elicio Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001601485
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				113430072
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-93548
		FILM NUMBER:		25515202

	BUSINESS ADDRESS:	
		STREET 1:		451 D STREET, 5TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02210
		BUSINESS PHONE:		(857) 209-0050

	MAIL ADDRESS:	
		STREET 1:		451 D STREET, 5TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02210

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Angion Biomedica Corp.
		DATE OF NAME CHANGE:	20140228

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Actyus Private Equity SGIIC, S.A.
		CENTRAL INDEX KEY:			0002050492
		ORGANIZATION NAME:           	
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			U3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13G

	BUSINESS ADDRESS:	
		STREET 1:		CALLE SERRANO 37
		CITY:			MADRID
		STATE:			U3
		ZIP:			28001
		BUSINESS PHONE:		34917453400

	MAIL ADDRESS:	
		STREET 1:		CALLE SERRANO 37
		CITY:			MADRID
		STATE:			U3
		ZIP:			28001
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13G
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13g" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<headerData>
<submissionType>SCHEDULE 13G</submissionType>
<filerInfo>
<filer>
<filerCredentials>
<cik>0002050492</cik>
<ccc>XXXXXXXX</ccc>
</filerCredentials>
</filer>
<liveTestFlag>LIVE</liveTestFlag>
</filerInfo>
</headerData>
<formData>
<coverPageHeader>
<securitiesClassTitle>Common Stock, par value $0.01 per share</securitiesClassTitle>
<eventDateRequiresFilingThisStatement>12/08/2023</eventDateRequiresFilingThisStatement>
<issuerInfo>
<issuerCik>0001601485</issuerCik>
<issuerName>Elicio Therapeutics, Inc.</issuerName>
<issuerCusip>28657F103</issuerCusip>
<issuerPrincipalExecutiveOfficeAddress>
<street1 xmlns="http://www.sec.gov/edgar/common">451 D Street</street1>
<street2 xmlns="http://www.sec.gov/edgar/common">5th Floor</street2>
<city xmlns="http://www.sec.gov/edgar/common">Boston</city>
<stateOrCountry xmlns="http://www.sec.gov/edgar/common">MA</stateOrCountry>
<zipCode xmlns="http://www.sec.gov/edgar/common">02210</zipCode>
</issuerPrincipalExecutiveOfficeAddress>
</issuerInfo>
<designateRulesPursuantThisScheduleFiled>
<designateRulePursuantThisScheduleFiled>Rule 13d-1(c)</designateRulePursuantThisScheduleFiled>
</designateRulesPursuantThisScheduleFiled>
</coverPageHeader>
<coverPageHeaderReportingPersonDetails>
<reportingPersonName>Actyus Private Equity SGIIC, S.A.</reportingPersonName>
<citizenshipOrOrganization>U3</citizenshipOrOrganization>
<reportingPersonBeneficiallyOwnedNumberOfShares>
<soleVotingPower>587818</soleVotingPower>
<sharedVotingPower>0</sharedVotingPower>
<soleDispositivePower>517818</soleDispositivePower>
<sharedDispositivePower>0</sharedDispositivePower>
</reportingPersonBeneficiallyOwnedNumberOfShares>
<reportingPersonBeneficiallyOwnedAggregateNumberOfShares>587818</reportingPersonBeneficiallyOwnedAggregateNumberOfShares>
<aggregateAmountExcludesCertainSharesFlag>N</aggregateAmountExcludesCertainSharesFlag>
<classPercent>5.45</classPercent>
<typeOfReportingPerson>IA</typeOfReportingPerson>
</coverPageHeaderReportingPersonDetails>
<items>
<item1>
<issuerName>Elicio Therapeutics, Inc.</issuerName>
<issuerPrincipalExecutiveOfficeAddress>The Company's principal executive office is located at 451 D Street, 5th Floor, Boston, Massachusetts, 02210.</issuerPrincipalExecutiveOfficeAddress>
</item1>
<item2>
<filingPersonName>This statement is filed by Actyus Private Equity SGIIC, S.A., a Sociedad Anonima organized under the laws of Spain ("Actyus" or the "Reporting Person"), with respect to the shares of Common Stock (as defined in Item 2(d) below) held by Azahar Private Capital, SCR, S.A., a Sociedad Anonima organized under the laws of Spain ("Azahar"). Actyus is the sole management company of Azahar and acts on behalf of Azahar investors' interests.</filingPersonName>
<principalBusinessOfficeOrResidenceAddress>The address of the business office of the Reporting Person is Calle Serrano 37, Madrid, 28001, Spain.</principalBusinessOfficeOrResidenceAddress>
<citizenship>Spain</citizenship>
</item2>
<item3>
<notApplicableFlag>Y</notApplicableFlag>
</item3>
<item4>
<amountBeneficiallyOwned>The percentage set forth in this Schedule 13G is calculated based upon an aggregate of  10,791,236 shares of Common Stock outstanding as of November 8, 2024, as reported in the Company's Registration Statement on Form 10Q filed with the Securities and Exchange Commission on November 13, 2024.</amountBeneficiallyOwned>
<classPercent>5.45%</classPercent>
<numberOfSharesPersonHas>
<solePowerOrDirectToVote>587,818</solePowerOrDirectToVote>
<sharedPowerOrDirectToVote>0</sharedPowerOrDirectToVote>
<solePowerOrDirectToDispose>587,818</solePowerOrDirectToDispose>
<sharedPowerOrDirectToDispose>0</sharedPowerOrDirectToDispose>
</numberOfSharesPersonHas>
</item4>
<item5>
<notApplicableFlag>Y</notApplicableFlag>
</item5>
<item6>
<notApplicableFlag>N</notApplicableFlag>
<ownershipMoreThan5PercentOnBehalfOfAnotherPerson>See Item 2.</ownershipMoreThan5PercentOnBehalfOfAnotherPerson>
</item6>
<item7>
<notApplicableFlag>Y</notApplicableFlag>
</item7>
<item8>
<notApplicableFlag>Y</notApplicableFlag>
</item8>
<item9>
<notApplicableFlag>Y</notApplicableFlag>
</item9>
<item10>
<notApplicableFlag>N</notApplicableFlag>
<certifications>By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under &amp;#167; 240.14a-11. </certifications>
</item10>
</items>
<signatureInformation>
<reportingPersonName>Actyus Private Equity SGIIC, S.A.</reportingPersonName>
<signatureDetails>
<signature>/s/ Jasmina Armengol</signature>
<title>Jasmina Armengol / Director of Finance and Operations</title>
<date>01/07/2025</date>
</signatureDetails>
<signatureDetails>
<signature>/s/ Alessia Carretie Columbo</signature>
<title>Alessia Carrestie Columbo / Director of Business Development</title>
<date>01/07/2025</date>
</signatureDetails>
</signatureInformation>
</formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
